NEUMORA THERAPEUTICS, INC. (NMRA) Cash and securities
- Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | (m) | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 116.83M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $116.83M | (m) | (m) |
| 2026-03-31 | (m) | (m) | $147.07M | (m) | (m) |
| 2025-12-31 | (m) | (m) | $182.53M | (m) | (m) |
| 2025-09-30 | $171.53M | (m) | $129.07M | $42.45M | (m) |
| 2025-06-30 | $217.59M | (m) | $124.52M | $93.06M | (m) |
| 2025-03-31 | $249.35M | (m) | $126.86M | $122.49M | (m) |
| 2024-12-31 | $307.58M | (m) | $142.15M | $165.43M | (m) |
| 2024-09-30 | $341.31M | (m) | $275.71M | $65.59M | (m) |
| 2024-06-30 | $371.64M | (m) | $150.68M | $220.96M | (m) |
| 2024-03-31 | $422.71M | (m) | $182.93M | $239.79M | (m) |
| 2023-12-31 | $453.98M | (m) | $374.04M | $79.94M | (m) |
| 2023-09-30 | $509.56M | (m) | $412.28M | $97.28M | (m) |
| 2023-06-30 | (m) | (m) | $204.22M | (m) | (m) |
| 2023-03-31 | (m) | (m) | $210.87M | (m) | (m) |
| 2022-12-31 | $371.88M | (m) | $240.94M | $130.94M | (m) |
| 2022-09-30 | (m) | (m) | $252.51M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |